{"_self":{"principle":"Self-explaining payload — no external context required. This _self block describes what you are reading and where to look next.","widget":"article_topology","feature":"topology","name":"Article topology","what":"Claims, sources, anecdotes, user reports, related embeds, question graph slice — for ask/ROUTER.","contains":"claims, sources, anecdotes, question_graph slice","slug":"retatrutide-chemo-neuropathy","urls":{"read":"https://miscsubjects.com/api/articles/retatrutide-chemo-neuropathy/topology"},"how_to_use":"Claims, sources, anecdotes, user reports, related embeds, question graph slice — for ask/ROUTER.","write":null,"imessage":null,"router_tag":null,"proof_chain":[{"step":1,"claim":"Articles are voxel graphs of tiered claims, not prose blobs.","verify":"https://miscsubjects.com/api/articles/constitution"},{"step":2,"claim":"Claims link to hash-chained sources via source_ids.","verify":"https://miscsubjects.com/api/articles/retatrutide-chemo-neuropathy/sources"},{"step":3,"claim":"Ask reads topology; ingest/claim append to ledger.","verify":"https://miscsubjects.com/api/protocol"},{"step":4,"claim":"Models queue growth: populate → collaborate → repair → reflex.","verify":"https://miscsubjects.com/api/protocol/grow"},{"step":5,"claim":"Graph proves its own shape (reflex) and $/claim (yield).","verify":"https://miscsubjects.com/graph.html?layer=reflex"},{"step":6,"claim":"Full feature index + _explain on every API response.","verify":"https://miscsubjects.com/api/articles/system-map"}],"related_features":[{"id":"ask","name":"Ask protocol","what":"Answer only from topology; creates question_node with gaps and ingest_hint.","urls":{"read":"https://miscsubjects.com/api/articles/retatrutide-chemo-neuropathy/prompts","write":"https://miscsubjects.com/api/protocol/ask"}},{"id":"graph_topology","name":"Cross-article graph","what":"Merged claims/sources across condition+stack slugs for one question.","urls":{"read":"https://miscsubjects.com/api/articles/retatrutide-chemo-neuropathy/graph-topology?question=..."}},{"id":"question_graph","name":"Question graph","what":"Ask nodes (questions + gaps) and evidence_ingest nodes (pasted model output).","urls":{"read":"https://miscsubjects.com/api/articles/retatrutide-chemo-neuropathy/question-graph","write":"https://miscsubjects.com/api/protocol/ask"}},{"id":"voxels","name":"Voxel graph","what":"Claims as atoms, sources as edges (supported_by, posted_by). Per-claim provenance.","urls":{"read":"https://miscsubjects.com/api/articles/retatrutide-chemo-neuropathy/voxels","write":"https://miscsubjects.com/api/protocol/claim"}}],"system_map":"https://miscsubjects.com/api/articles/system-map","system_map_markdown":"https://miscsubjects.com/api/articles/system-map?format=markdown","not_medical_advice":true},"_explain":{"feature":"topology","name":"Article topology","what":"Claims, sources, anecdotes, user reports, related embeds, question graph slice — for ask/ROUTER.","why":"Every feature is auditable collective intelligence","how":"Claims, sources, anecdotes, user reports, related embeds, question graph slice — for ask/ROUTER.","model":null,"verifies":null,"urls":{"read":"https://miscsubjects.com/api/articles/retatrutide-chemo-neuropathy/topology"},"imessage":null,"router":null,"related":[{"id":"ask","what":"Answer only from topology; creates question_node with gaps and ingest_hint."},{"id":"graph_topology","what":"Merged claims/sources across condition+stack slugs for one question."},{"id":"question_graph","what":"Ask nodes (questions + gaps) and evidence_ingest nodes (pasted model output)."},{"id":"voxels","what":"Claims as atoms, sources as edges (supported_by, posted_by). Per-claim provenance."}],"not_medical_advice":true},"slug":"retatrutide-chemo-neuropathy","title":"Retatrutide for Chemotherapy-Induced Neuropathy: A Data-First Evidence Review","register":"source_ledger","tags":["peptide","matrix"],"updated_at":"2026-07-17T02:41:15.460Z","body_excerpt":"## What's breaking down if you have Chemotherapy-induced neuropathy (CIPN)\n\nChemotherapy-induced peripheral neuropathy (CIPN) involves damage to peripheral nerves from certain chemo agents like taxanes, platinums, and vinca alkaloids. This leads to sensory symptoms such as numbness, tingling, burning pain, and reduced function that can last months or years after treatment ends. Prevalence reaches 68% at one month, 60% at three months, and 30% at six months post-chemo in systematic reviews of over 4,000 patients (human tier, source s9).\n\nDegeneration layers include direct axonal toxicity, mitochondrial dysfunction in neurons, oxidative stress, and neuroinflammation. These processes outpace natural repair mechanisms, leaving persistent nerve impairment. Excess body weight can add mechanical stress on nerves and joints, but CIPN itself stems primarily from chemo exposure rather than load alone. Repair pathways focus on reducing inflammation and supporting nerve recovery; symptom-masking approaches do not address the underlying breakdown.\n\n## Why Retatrutide might help you\n\n1. You are reading about **Chemotherapy-induced neuropathy (CIPN)** — what breaks down matters before any compound name.\n2. **What keeps failing:** Excess body weight multiplies compressive load on spine, hips, knees, and plantar fascia.\n3. **What Retatrutide is studied to do:** Studied for GLP-1/GIP/glucagon-driven weight loss — less mechanical load, not direct disc regeneration.\n4. **Therefore for you:** If that layer is part of your problem, Retatrutide is discussed because it targets repair (metabolic load / body weight) — not because it masks pain.\n\nIf your CIPN profile includes elevated body weight that increases overall physical stress on already damaged nerves, retatrutide's studied effects on substantial weight reduction could indirectly ease that component. Phase 2 human trials showed mean weight loss of 17-24% at 48 weeks with higher doses versus 2% on placebo (human tier, source s2). Phase 3 data reported averages near 28% loss over 80 weeks (human tier, source s3). This metabolic shift addresses load without claiming nerve repair. No direct studies link it to CIPN axon recovery.\n\n## Why Gabapentin / pregabalin matters for you\n\n**Drug:** Gabapentin / pregabalin\n**What it does:** Masks neuropathic pain signal; does not repair nerve.\n**Therefore for you:** This drug suppresses a signal. It may ease pain perception in some neuropathic conditions but does not support nerve repair pathways and shows inconsistent or null results specifically in CIPN trials, trading potential symptom relief for possible side effects without addressing degeneration.\n\nMeta-analyses of human trials found pregabalin did not significantly prevent or reduce average pain in CIPN versus placebo (human tier, source s18). Some smaller studies note inconsistent benefits for treatment, with no reliable advantage over placebo overall. It targets symptom suppression rather than regeneration.\n\n## How these fit together\n\nSingle-compound focus — retatrutide targets metabolic load / body weight. Gabapentin / pregabalin targets signal suppression. If your CIPN involves both excess weight adding mechanical stress and ongoing pain signals, the two address separate layers without overlap in repair mechanisms. Retatrutide supports metabolic improvement that could reduce secondary load; the drug provides symptomatic masking that does not aid long-term nerve recovery. No synergy data exists for this pairing in CIPN.\n\n## What the evidence actually shows\n\nHuman trials: Retatrutide phase 2 (NEJM) and phase 3 TRIUMPH-1 confirm dose-dependent weight loss up to ~24-28% body weight in adults with obesity (human tier). No human trials test retatrutide in CIPN patients.\n\nGabapentin/pregabalin: Multiple randomized human trials and meta-analyses show limited or no benefit for CIPN prevention or treatment compared to placebo; results inconsistent across studies (human tier).\n\nPreclinical: No animal data on re","ranking":"safety-first (interaction_risk/limitations), then quote-gated effective_weight","claims":[{"id":"c5","text":"No human trials test retatrutide directly in CIPN patients.","tier":"human","weight":0.8,"section":"What the evidence actually shows","slot":null,"interaction_risk":false,"status":"active","source_ids":[],"source_status":"unsourced","why_material":"Highlights absence of direct data.","retracted_at":null,"retraction_reason":null,"challenged_by":[],"effective_weight":0.8,"quote_gated":false},{"id":"c1","text":"CIPN prevalence reaches 68% at one month post-chemo in systematic reviews.","tier":"human","weight":0.8,"section":"What's breaking down if you have Chemotherapy-induced neuropathy (CIPN)","slot":null,"interaction_risk":false,"status":"active","source_ids":["s9"],"source_status":"sourced","why_material":"Establishes scale of condition for readers with CIPN.","retracted_at":null,"retraction_reason":null,"challenged_by":[],"effective_weight":0.22,"quote_gated":true},{"id":"c2","text":"Retatrutide phase 2 trials showed 17-24% mean weight loss at 48 weeks vs 2% placebo.","tier":"human","weight":0.8,"section":"Why Retatrutide might help you","slot":null,"interaction_risk":false,"status":"active","source_ids":["s2"],"source_status":"sourced","why_material":"Documents metabolic effect tied to the proposed load-reduction pathway.","retracted_at":null,"retraction_reason":null,"challenged_by":[],"effective_weight":0.22,"quote_gated":true},{"id":"c3","text":"Phase 3 TRIUMPH-1 reported ~28% average weight loss over 80 weeks with retatrutide.","tier":"human","weight":0.8,"section":"Why Retatrutide might help you","slot":null,"interaction_risk":false,"status":"active","source_ids":["s3"],"source_status":"sourced","why_material":"Confirms substantial weight reduction in larger human data set.","retracted_at":null,"retraction_reason":null,"challenged_by":[],"effective_weight":0.22,"quote_gated":true},{"id":"c4","text":"Meta-analysis found pregabalin did not significantly reduce average CIPN pain vs placebo.","tier":"human","weight":0.8,"section":"Why Gabapentin / pregabalin matters for you","slot":null,"interaction_risk":false,"status":"active","source_ids":["s18"],"source_status":"sourced","why_material":"Shows limited evidence for symptom suppression in this specific condition.","retracted_at":null,"retraction_reason":null,"challenged_by":[],"effective_weight":0.22,"quote_gated":true}],"sources":[{"id":"s9","type":"pubmed","url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC11674975/","title":"Chemotherapy-Induced Peripheral Neuropathy: Assessment ...","quote":"Seretny et al. (2014) conducted a large systematic review with 4,179 patients and found that the prevalence of CIPN after chemotherapy was 68% at one month, 60% at three months, and 30% at six months.","summary":"Systematic review on CIPN prevalence and persistence.","claim_ids":["c1"],"link_status":"ok","quote_status":"unverified","hash":"05a630838dba6977085a404a90a897530183d0834d7981e78f983ce958cce286"},{"id":"s2","type":"pubmed","url":"https://www.nejm.org/doi/full/10.1056/NEJMoa2301972","title":"Triple–Hormone-Receptor Agonist Retatrutide for Obesity","quote":"At 48 weeks, the least-squares mean percentage change in the retatrutide groups was −8.7% in the 1-mg group, −17.1% in the combined 4-mg group, −22.8% in the combined 8-mg group, and −24.2% in the 12-mg group, as compared with −2.1% in the placebo group.","summary":"Phase 2 human trial results on retatrutide weight loss.","claim_ids":["c2"],"link_status":"http_403","quote_status":"unverified","hash":"9709de18985082872356613666a60434cb92314cc06f2d6d0c4d260a36ec6e8b"},{"id":"s3","type":"news","url":"https://investor.lilly.com/news-releases/news-release-details/lillys-triple-agonist-retatrutide-delivered-powerful-weight-loss","title":"Lilly's triple agonist, retatrutide, delivered powerful weight loss...","quote":"In TRIUMPH-1, participants on 12 mg retatrutide lost an average of 70.3 lbs (28.3%) over 80 weeks...","summary":"Phase 3 trial summary from manufacturer.","claim_ids":["c3"],"link_status":"ok","quote_status":"unverified","hash":"4cd73093960c9184759edb345ec02110fb6b75c829578d8934891c80798b36f1"},{"id":"s18","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/38936970/","title":"Gabapentinoids for chemotherapy-induced peripheral ...","quote":"For the prevention setting, our meta-analysis shows that pregabalin did not significantly improve average pain (standardised mean difference (SMD) -0.14, 95% CI -0.51 to 0.23...","summary":"Meta-analysis on gabapentinoids in CIPN.","claim_ids":["c4"],"link_status":"ok","quote_status":"unverified","hash":"f46e7ff141247166dfadb85f52b95aa05dc25a029bc85b486fc5c91540d1fcd9"}],"anecdotal_sources":[],"scientific_sources":[{"id":"s9","type":"pubmed","url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC11674975/","title":"Chemotherapy-Induced Peripheral Neuropathy: Assessment ...","quote":"Seretny et al. (2014) conducted a large systematic review with 4,179 patients and found that the prevalence of CIPN after chemotherapy was 68% at one month, 60% at three months, and 30% at six months.","summary":"Systematic review on CIPN prevalence and persistence.","claim_ids":["c1"],"link_status":"ok","quote_status":"unverified","hash":"05a630838dba6977085a404a90a897530183d0834d7981e78f983ce958cce286"},{"id":"s2","type":"pubmed","url":"https://www.nejm.org/doi/full/10.1056/NEJMoa2301972","title":"Triple–Hormone-Receptor Agonist Retatrutide for Obesity","quote":"At 48 weeks, the least-squares mean percentage change in the retatrutide groups was −8.7% in the 1-mg group, −17.1% in the combined 4-mg group, −22.8% in the combined 8-mg group, and −24.2% in the 12-mg group, as compared with −2.1% in the placebo group.","summary":"Phase 2 human trial results on retatrutide weight loss.","claim_ids":["c2"],"link_status":"http_403","quote_status":"unverified","hash":"9709de18985082872356613666a60434cb92314cc06f2d6d0c4d260a36ec6e8b"},{"id":"s18","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/38936970/","title":"Gabapentinoids for chemotherapy-induced peripheral ...","quote":"For the prevention setting, our meta-analysis shows that pregabalin did not significantly improve average pain (standardised mean difference (SMD) -0.14, 95% CI -0.51 to 0.23...","summary":"Meta-analysis on gabapentinoids in CIPN.","claim_ids":["c4"],"link_status":"ok","quote_status":"unverified","hash":"f46e7ff141247166dfadb85f52b95aa05dc25a029bc85b486fc5c91540d1fcd9"}],"user_reports":[],"related_articles":[],"question_graph":{"slug":"retatrutide-chemo-neuropathy","questions":[],"evidence":[],"edges":[],"counts":{"questions":0,"evidence":0,"edges":0}},"honesty":{"active_claims":5,"retracted_claims":0,"cut_claims":0,"challenges":0,"scrub_events":0,"note":"Retracted/cut claims stay on ledger but are excluded from ask unless ?include_inactive=1"},"counts":{"claims":5,"claims_total":5,"sources":4,"anecdotal":0,"scientific":3,"user_reports":0,"questions":0,"evidence_ingests":0}}